Domov › Crohnova bolezen › Missouri
Klinične študije za Crohnova bolezen v Missouri
21 študij za Crohnova bolezen išče udeležence na lokacijah v Missouri.
Mesta v Missouri
Uradno besedilo študije (angleško)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- BVL Research - Kansas ( Site 0292), Liberty
Vključevanje udeležencevFaza 3
Vse starosti · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Mid-America GI Clinical Research ( Site 5130), Kansas City
- BVL Research - Kansas ( Site 5099), Liberty
- Washington University School of Medicine ( Site 5058), St Louis
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Specialists In Gastroenterology /ID# 283939, St Louis
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- SSM Health Medical Group, Bridgeton
- GI Associates Research, LLC, Columbia
- Mid America Gastro Intestinal Consultants, Kansas City
- in še 1
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- GI Associates Research, LLC /ID# 267433, Columbia
- Bvl Research /ID# 265870, Liberty
- Washington University /ID# 266938, St Louis
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06548542A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research, Liberty
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- in še 6
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Washington University School of Medicine-Site Number: 8400075, St Louis
- Gateway Gastroenterology-Site Number: 8400097, St Louis
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- BVL Clinical Research-Site Number: 8400005, Liberty
- Gateway Gastroenterology-Site Number: 8400097, St Louis
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- SSM Health DePaul Hospital- St. Louis, Bridgeton
Vključevanje udeležencevFaza 2
Starost 18–85 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- KAD Clinical Research, St Louis
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 3
Starost 2–19 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT04844606A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- KAD Clinical Research, St Louis
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Mid-America Gastro-Intestinal Consultants, Kansas City
- BVL Clinical Research, Liberty
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 4
Starost 18–70 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06045754DB-3Q for the Treatment of Medically Refractory Crohn's Disease
- Washington University, St. Louis, St Louis
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT07625293Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 5. jun. 2026 · NCT06976853A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400013, St Louis
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 27. mar. 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Washington University in St. Louis, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18–65 · Vsi spoli · Posodobljeno 10. dec. 2025 · NCT06721962Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
- Washington University in St Louis School of Medicine, St Louis
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 12. nov. 2025 · NCT06670638Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.